Collaborative Care for Opioid Use Disorder and Mental Health Conditions
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial aims to improve care for individuals with both opioid use disorder (OUD) and mental health issues such as depression, anxiety, or PTSD. It will test various care methods in primary care settings, including standard care and enhanced collaborative care models, some of which include a certified recovery specialist to support recovery. The trial suits those diagnosed with OUD within the past year and experiencing challenges with depression, anxiety, or PTSD. Participants should be open to receiving medication for OUD at their primary care clinic.
As an unphased trial, this study offers a unique opportunity to contribute to innovative care models that could enhance treatment for OUD and mental health issues.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, you must agree to receive medication for opioid use disorder at the primary care site.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that collaborative care models can improve access to and quality of treatment for individuals with opioid use disorder (OUD) and mental health issues such as depression, anxiety, and PTSD. While studies do not highlight specific safety details for these care models, their common use in medical settings suggests they are generally considered safe.
Regarding the addition of Certified Recovery Specialists (CRS) to the collaborative care model, specific safety data is unavailable. However, the CRS role supports patients in their treatment and offers peer support, which is viewed as helpful and positive in recovery settings, indicating it is well-accepted.
The absence of detailed safety data may be because this trial focuses on enhancing existing care models rather than testing a new drug or treatment. This typically implies that the treatment methods are considered relatively safe, as they are already in use.12345Why are researchers excited about this trial?
Researchers are excited about these treatments because they offer a more integrated approach to tackling opioid use disorder (OUD) combined with mental health conditions. Unlike traditional care, the Collaborative Care model incorporates a dedicated care manager and an addictions psychiatrist to guide treatment, ensuring holistic attention to both substance use and mental health. The addition of Certified Recovery Specialists (CC+) is particularly promising as it introduces peer support, potentially boosting patient engagement and retention by providing personalized navigation and support from someone who has faced similar challenges. This comprehensive, team-based approach could lead to more effective management of both OUD and associated mental health issues, offering hope for better patient outcomes.
What evidence suggests that this trial's treatments could be effective for opioid use disorder and mental health conditions?
Research shows that team-based care for treating opioid addiction and mental health issues holds promise. In this trial, participants may receive one of several treatment approaches. Studies have found that the Collaborative Care model, one of the study arms, greatly reduces opioid use and aids with mental health problems like depression and anxiety, which often accompany opioid addiction. Another arm, Collaborative Care Plus Certified Recovery Specialist (CC+), includes a Certified Recovery Specialist (CRS) who provides extra support through peer guidance and helps patients stay committed to their treatment. This approach aims to improve overall health and recovery by addressing both addiction and mental health needs together.12346
Who Is on the Research Team?
David Mandell, PhD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for adults over 18 with opioid use disorder and a mental health condition like depression, anxiety, or PTSD. Participants must have been diagnosed or treated for OUD within the last year, speak English, consent to treatment at the primary care site using buprenorphine-naloxone or naltrexone injections, and be willing to give informed consent. Those acutely suicidal, manic, psychotic or without a phone are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive collaborative care for OUD and mental health conditions, including pharmacotherapy and care management
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- Augmented Usual Care
- Collaborative Care for Opioid Use Disorders and Mental Health Conditions
- Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor
Weill Medical College of Cornell University
Collaborator